1. Home
  2. IDYA vs RNW Comparison

IDYA vs RNW Comparison

Compare IDYA & RNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • RNW
  • Stock Information
  • Founded
  • IDYA 2015
  • RNW 2011
  • Country
  • IDYA United States
  • RNW United Kingdom
  • Employees
  • IDYA N/A
  • RNW N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • RNW Electric Utilities: Central
  • Sector
  • IDYA Health Care
  • RNW Utilities
  • Exchange
  • IDYA Nasdaq
  • RNW Nasdaq
  • Market Cap
  • IDYA 2.9B
  • RNW 2.7B
  • IPO Year
  • IDYA 2019
  • RNW N/A
  • Fundamental
  • Price
  • IDYA $34.21
  • RNW $7.51
  • Analyst Decision
  • IDYA Buy
  • RNW Buy
  • Analyst Count
  • IDYA 14
  • RNW 2
  • Target Price
  • IDYA $49.58
  • RNW $7.83
  • AVG Volume (30 Days)
  • IDYA 992.0K
  • RNW 1.6M
  • Earning Date
  • IDYA 11-04-2025
  • RNW 11-10-2025
  • Dividend Yield
  • IDYA N/A
  • RNW N/A
  • EPS Growth
  • IDYA N/A
  • RNW 413.66
  • EPS
  • IDYA N/A
  • RNW 0.26
  • Revenue
  • IDYA $214,834,000.00
  • RNW $1,382,164,625.00
  • Revenue This Year
  • IDYA $90.17
  • RNW N/A
  • Revenue Next Year
  • IDYA $217.29
  • RNW $16.58
  • P/E Ratio
  • IDYA N/A
  • RNW $28.75
  • Revenue Growth
  • IDYA 5377.66
  • RNW 46.76
  • 52 Week Low
  • IDYA $13.45
  • RNW $5.42
  • 52 Week High
  • IDYA $34.66
  • RNW $8.24
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 68.23
  • RNW 48.50
  • Support Level
  • IDYA $31.15
  • RNW $7.22
  • Resistance Level
  • IDYA $34.66
  • RNW $7.61
  • Average True Range (ATR)
  • IDYA 1.58
  • RNW 0.12
  • MACD
  • IDYA 0.11
  • RNW 0.02
  • Stochastic Oscillator
  • IDYA 89.86
  • RNW 75.00

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About RNW ReNew Energy Global plc

ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.

Share on Social Networks: